TABLE 110Carer-proxy HRQoL from Jonsson and colleagues187

MMSE scoreAverage carer-proxy EQ-5D, EQ-5D VAS and QoL-AD utilitiesaEQ-5D where both carer and patient ratings were availableEQ-5D where just carer ratings were available
26–300.690.70.5
21–250.640.650.19
15–200.50.520.21
10–140.490.510.39
0–90.330.40.22
a

As used in the PenTAG base case.

As used in the PenTAG base case.

From: 6, The Peninsula Technology Assessment Group cost–utility assessment

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.